-
Healthcare reform law provisions could affect pharmaceutical innovation, Bristol-Myers Squibb exec says
WASHINGTON — Drug maker Bristol-Myers Squibb foresees significant effects on its business from the Patient Protection and Affordable Care Act, company executives told attendees of the its recent shareholder meeting.